Pharmaceutical and biotech companies know that if they decide to provide access to their medicines prior to commercial launch, they need to plan early.
They need to consider the short- and long-term operational and strategic implications.
They need to proceed in a way that ensures the right patients get access, that provides healthcare professionals with the information and support they need to safely treat their patients, and that can be rolled out at a national, regional, or global level.
They need to do so in a way that’s efficient, cost-effective, and maximises value for all their stakeholders – patients, healthcare professionals and themselves.
That’s where Clinigen come in.
As pioneers in early access and compassionate use, with more than 30 years’ experience across 100+ countries, Clinigen work in partnership with pharma companies to design and implement Managed Access Programs that serve their clients and help treat patients.
They recognise that every client has different goals, and every patient has different challenges – there is no one-size-fits-all.
Clinigen’s flexible approach and industry-leading experience mean that their clients get the right solution – and patients get the right medicine.